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ABSTRACT: Molecular probes that selectively highlight pancreatic cancer (PC)
tissue have the potential to improve pancreatic ductal adenocarcinoma (PDAC)
margin assessment through the selective highlighting of individual PC cells.
Herein, we report a simple and unique family of systematically modified red and
near-infrared fluorescent probes that exhibit a field-effect-derived redshift. Two of
thirteen probes distributed to the normal mouse pancreas following systemic
administration. One selectively accumulated in genetically modified mouse models
of PDAC. The probe exhibited intracellular accumulation and enabled
visualization of four levels of the structure, including the whole organ, resected
tissue, individual cells, and subcellular organelles. In contrast to the small-molecule
probes reported previously, it possesses an inherent affinity toward PDAC cells
and thus does not require conjugation to any targeting agent. The fluorescent
probe can thus promote new strategies not only for precision image-guided
surgery, but also for PC detection, monitoring of therapeutic outcomes, and basic
research.
■ INTRODUCTION
It was estimated that approximately 53 000 people would have
been diagnosed with pancreatic cancer (PC) in the United
States in 2016 and would have had a postdiagnosis life
expectancy of 5−7 months.1 PC is projected to become the
second leading cause of cancer-related death by 2030.2
Pancreatic ductal adenocarcinoma (PDAC) is the most
prevalent form of PC. Current screening for PDAC using
techniques such as magnetic resonance imaging and computed
axial tomography is relatively expensive and ineffective, as over
half of all cases are diagnosed after metastasis has occurred,
limiting treatment options. Surgical resection is the treatment
of choice because chemotherapy and/or radiation therapy alone
do not significantly improve life expectancy.3 Unfortunately,
surgical resection is only possible in 15−20% of cases.4
Moreover, to date there has been no intraoperative guidance
to differentiate malignant pancreas from normal pancreatic
tissues. PC and healthy tissue are currently distinguished
through white light visualization and palpation as well as by
rapid frozen section (FS) analysis using histopathological
pattern recognition through standard hematoxylin and eosin
(H&E) staining while the surgical resection is in progress.5
Intraoperative assessment of PDAC margin status during
surgery is challenging using current technology. Nearly 75% of
all patients have residual disease from margins not assessed by
FS analysis. Limitations of FS analysis include negative
assessments due to time constraints in the operating room
and microscopic metastases not detected at the time of
surgery.6 In addition, cellular architecture distortion and tissue
artifacts are common issues that occur during FS sample
preparation. Slides produced by formalin-fixed paraffin-
embedded tissue processing would be highly desirable over
FS-based H&E; however, it is well known that the tissue
processing time is too lengthy for intraoperative use.
Fluorescence imaging has the potential to improve PDAC
detection during surgery via the use of highly tumor-specific
molecular probes to facilitate tumor identification. It offers the
potential for less subjective, rapid, real-time ex vivo
confirmation of negative margin status during surgery. Near-
infrared (NIR) fluorophores have excitation and emission
maxima between 650 and 900 nm, where hemoglobin and H2O
have their lowest absorption coefficients. Moreover, NIR
phonons cause minimal photoinduced damage to biological
samples and have relatively high tissue penetration depth and
signal-to-background ratios (SBRs). Therefore, NIR probes can
enhance the overall image quality and collection time.
However, to date there are no clinically approved PC-specific
fluorescent dyes. Commercially available dyes, including the
only FDA-approved in vivo fluorescent contrast agents,
indocyanine green, methylene blue (MB), and fluorescein,
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exhibit nonspecific fluorescence and largely act as blood pool
agents.
■ RESULTS AND DISCUSSION
One of the main challenges in PDAC therapy is drug delivery
and is largely attributed to the hypovascular and fibrotic tumor
microenvironment.7 Thus, to attain desirable PDAC-selective
accumulation and SBR, we have synthesized a focused library of
systematically modified 1-substituted benzo[c]xanthene fluo-
rophores (Figure 1) to begin to define factors modulating tissue
biodistribution,8 such as probe size, lipophilicity, solubility, and
ionization state. To minimize the effects of autofluorescence,
these compounds were designed to exhibit significant bath-
ochromic shifts compared to traditional long-wavelength 3-
substituted benzo[c]xanthenes via the formal repositioning of
polar groups.9−12
Compounds 1−13 (Figure 1) were designed taking into
account the uptake and related “drug-like” properties that can
be used as quantitative descriptors for predicting and
optimizing biodistribution and tissue targeting.13 The predicted
absorption spectra and physicochemical properties of 1−13 are
shown in Figures S1−S3 (Supporting Information (SI)).
Compounds 1−13 exhibit maximum absorption peaks between
400 and 650 nm and are within the requirements to be
considered for tissue targeting according to the Lipinski14 and
Veber15 rules. LogD values ranged from 0.5 to 5 (Lipinski rule:
<5), molecular weights were between 400 and 500 g/mol
(Lipinski rule: <500 g/mol), 0−4 hydrogen bond donors
(Lipinski rule: <5) and 4−5 hydrogen bond acceptors (Lipinski
rule: <10) were present, and polar surface areas ranged between
48 and 87 Å2 (Veber rule: <140 Å2). Experimental details for
the synthesis of each compound are provided in the SI.
The spectral properties of this series of probes (1−13), based
on seminaphthofluorescein, seminaphthorhodafluor, and semi-
naphthorhodamine scaffolds, were screened for pH and solvent
dependence (Figure 2, Table 1, and Figures S4−S9).
Absorption and fluorescence spectra of compounds containing
ionizable hydroxyl groups (seminaphthofluorescein 1 and
seminaphthorhodafluors 3, 5, and 11) exhibited pH depend-
ence over the physiological range (Figures S4 and S5) and
solvatochromic effects (Figure S5). In aqueous solution, the
hydroxyl forms of 1, 3, 5, and 11 were red emitting, whereas
their conjugate bases exhibited NIR fluorescence. Solvent
dependence is at least partially attributable to differences in the
equilibria between tautomeric forms of the compounds in the
various solvents tested. Solvent and pH sensitivity were
addressed via derivatization. Methoxy-functionalized analogues
(2, 4, 6, and 12) displayed relatively bright red fluorescence and
were independent of variations in pH (Figures S6 and S7) and
solvent composition (Figure S7). Replacing the hydroxyl group
with an amine generated a series of NIR-emitting semi-
naphthorhodamines (9, 10, and 13). The spectral properties of
9, 10, and 13 were pH independent and only modestly
dependent on solvent composition (Figure S8). Transposition
of the hydroxyl and amine functionalities in seminathorhoda-
fluors 3 and 5 generated compounds 7 and 8. This lowered
their pKa values, resulting in spectral properties that were not
pH dependent in the physiological range.
Compounds 2, 12, and 13 are representative of the three
classes of benzo[c]xanthenes designed in this study and were
chosen as candidates for initial in vivo and ex vivo screening for
pancreas and PDAC targeting based on the following
considerations. First, their predicted physiochemical properties
(Figures S1−S3) cover a relatively broad range of logD values,
enabling evaluation of the influence of lipophilicity on targeting.
Second, each exhibits desirable pH independence. Third, their
spectral properties (Figures S6−S8) show that they have the
highest quantum yield and brightness within each of the three
classes of benzo[c]xanthenes. The predicted physicochemical
properties of 2, 12, and 13 are shown in Figure 3, allowing
correlation between the in vitro and in vivo targeted
localization and the molecular characteristics of the synthesized
fluorophores. In vitro cell viability (Figure S10A) and time-
dependent fluorophore uptake (Figure S10B) were assessed in
the presence of compounds 2, 12, and 13 in Capan-1 cells (a
representative PDAC cell line). The cytotoxicity studies
demonstrated that compound 2 was the least toxic (IC50
30.08 μM), followed by compounds 13 (IC50 26.08 μM) and
12 (IC50 17.79 μM). Each fluorophore exhibited similar
kinetics, demonstrating uptake within 30 min of fluorophore
application. Compound 13 exhibited the greatest uptake and 2
the lowest during this period.
The subcellular localization of 2, 12, and 13 was investigated
in Capan-1 cells after 1 h incubation. Organelle-specific
fluorescent probes were used to assess the site-specific uptake
of each fluorophore. The preferential intracellular localization
of compound 2 (Figure S10C) was within vesicular structures
that may embody lipid droplets, endosomes, or other
membrane-based vesicles. In contrast to 2, compounds 12
(Figure 4) and 13 (Figure S10E) demonstrated more
homogeneous distribution across cells with extensive accumu-
lation in the mitochondria (Mito) as well as limited
accumulation in the nucleus and endoplasmic reticulum (ER).
12 and 13 are cationic, and they distribute electrophoretically in
the mitochondrial matrix in response to the electric potential
across the mitochondrial membrane.16
The initial biodistribution profile screening of 2, 12, and 13
was carried out in healthy CD-1 mice and compared to that of
MB to assess their pancreas specificity (Figure 5). Compound
12 exhibited the highest and most persistent fluorescence SBR
in the pancreas as compared to that in the surrounding organs
at the 4 h time point. It had a 4-fold higher uptake in normal
pancreas tissue as compared to that of previously studied MB
Figure 1. 1-Substituted benzo[c]xanthene library.
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(log D = −0.62). MB extravasated to some degree but
demonstrated poor penetration into normal pancreas tissue
(Figure S11). The low in vivo efficacy of MB could be
attributed to its relatively low lipophilicity and high water
solubility, as it is preferentially and rapidly cleared through the
renal system after systemic administration. MB’s low tissue
fluorescence, rapid clearance rate, and reduced bioavailability
limited its pancreas tissue selectivity and thus its potential for
image-guided surgery applications. From the study herein,
higher logD value compounds 2 and 12 exhibited improved
pancreas specificity, whereas 13 and MB had relatively lower
logD values and diminished pancreas accumulation, which
correlates well with previous studies.13,17
Genetically engineered mouse models of PDAC tumors that
recapitulate the clinical, pathological, and genomic features of
human PDAC18,19were used to assess the specificity of the
designed fluorophores for PDAC accumulation both in vivo
and ex vivo. Compound 12, which afforded the highest
pancreas tissue uptake in healthy mice, was chosen for further
study in the genetically modified PDAC tumor-bearing mouse
model. Ex vivo staining of pancreas tissue derived from healthy
and PDAC mice showed that their characteristic features were
highlighted by 12 (Figure 6A). The healthy mouse pancreas
tissue showed uptake of 12 in its abundant acinar cell
population. In contrast, in the cancerous tissue, 12 localized
in the PDAC-associated ductal epithelial cells, enabling them to
be observed via an increased fluorescence signal that was
visually brighter compared to that of the acinar cells in the
healthy tissue. Thus, 12 enabled ex vivo staining to distinguish
the features of healthy and PDAC tissue ex vivo (Figure 6A).
Compound 12 was systemically administered to n = 5
genetically modified PDAC mice. Pancreas-specific fluorescence
was monitored over a 1.5 h period. Significantly more
fluorescence was seen in compound 12-injected PDAC-bearing
animals compared to that in uninjected control PDAC-bearing
animals (Figure 6B,C). After euthanasia, the pancreas was
assessed microscopically for PDAC-specific fluorophore accu-
mulation. Representative intraoperative fluorescence images
over time as well as the in vivo organ biodistribution kinetics of
compound 12 are shown in Figure S12.
Representative serially sectioned tissues stained with pan-
cytokeratin to assess PDAC specificity of compound 12
Figure 2. Spectral properties of compounds 1−13 at various pH values. (A) Absorption spectra (solid lines) and normalized fluorescence emission
spectra (dash lines) of pH-dependent seminaphthofluorescein and seminaphthorhodafluors (1, 3, 5, and 11) in acidic solution (pH 1.9, HCl). (B)
Conjugate bases of 1, 3, 5, and 11 in basic solution (pH 12.1, NaOH). (C) pH-independent seminaphthofluorescein and seminaphthorhodafluors
(2, 4, 6, and 12) in pH 7.4 buffer. (D) pH-independent seminaphthorhodamines (9, 10, and 13) in pH 7.4 buffer. (E) Conjugate acids of transposed
seminaphthorhodafluors (7 and 8) in acidic solution (pH 1.9, HCl). (F) 7 and 8 in basic solution (pH 12.1, NaOH). Fluorophore concentrations
range from 10 to 15 μM. Aqueous solutions contain 10% DMSO and 12.5 mM HCl, NaOH or pH 7.4 buffer. Red-emitting fluorophores were
excited at 480 or 510 nm, and NIR-emitting fluorophores were excited at 630 nm. Emission spectra are normalized to their corresponding absorption
peaks. Excitation Emission Matrices (EEMs) are provided in the SI.
ACS Omega Article
DOI: 10.1021/acsomega.6b00403
ACS Omega 2017, 2, 154−163
156
confirmed that accumulation of compound 12 in the PDAC
tumor tissue was significantly higher than that in the
surrounding tissues and that compound 12 showed specificity
for the malignant cells (Figure 7). H&E staining of the PDAC
specimens revealed that uptake of 12 occurred in ductal tissue
epithelial cells, similar to the ex vivo staining pattern (Figures
6A and 7). This is consistent with the fact that pancreatic ductal
epithelial cells give rise to PDAC.20 Furthermore, the
accumulation of 12 in PDAC mouse acinar cells (Figure 7D)
also demonstrated colocalization with the pan-cytokeratin
immunofluorescence staining. This supports studies that have
shown that genetic mutations of acinar cells are associated with
precancerous pancreatic intraepithelial neoplasia that pro-
gresses to PDAC over time.21,22
■ CONCLUSIONS
In summary, the synthesis of a focused probe library with
predictable physicochemical properties afforded a simple
molecular probe (12), enabling the imaging of PDAC in a
genetically engineered mouse model both in vivo and ex vivo,
providing the opportunity for dual clinical utility. Compound
12 offers highly attractive characteristics, such as high contrast,
tumor specificity, and adaptation to clinical and intraoperative
workflows. Conjugation to a biological targeting agent was not
required for PDAC tumor specificity. Compound 12
functioned at the level of the whole organ, enabling
visualization of a cancerous pancreas with excellent SBR. It
targeted PDAC tissue and cells as evidenced by comparison
with H&E staining and the immunohistochemistry pan-
cytokeratin assay, and it allowed for ready distinction between
individual cell morphologies. At the subcellular level, it
demonstrated accumulation in the mitochondria. Compound
12 is highly tumor specific, enabling the imaging of PDAC at
four different levels of structure in a genetically engineered
mouse model. It thus possesses desirable properties for
promoting enhanced PC detection, therapeutic monitoring,
and image-guided surgery.
■ METHODS
Prediction of Physicochemical Properties and Molec-
ular Modeling. Physicochemical partition coefficient (log D)
values at pH 7.4 were calculated using Marvin and JChem
calculator plugins (ChemAxon, Budapest, Hungary). Molecular
Table 1. Tabulated Spectral Properties of Compounds 1−13









1 530 (12 167) 600 (1.17) 70 142 7.72
2 530 (15 610) 580 (46.49) 50 7257
3 542 (19 787) 604 (1.14) 62 226 6.67
4 538 (21 742) 596 (34.42) 58 7484
5 567 (20 399) 614 (4.09) 47 834 6.82
6 568 (22 470) 606 (9.32) 38 2094
7 509 (8300) 530 21
7 549 (5664) 750 201
8 530 (8834) 530 21
9 576 (13 872) 760 (0.18) 184 25
10 598 (17 066) 770 (0.20) 172 34
11 585 (15 134) 624 (15.3) 39 2314 7.84
12 582 (17 764) 622 (11.38) 40 2022
13 601 (12 808) 740 (0.66) 139 85
aFluorophore concentrations range from 10 to 15 μM. Aqueous
solutions contain 10% DMSO and 12.5 mM HCl, NaOH or pH 7.4
phosphate buffer. Tabulated spectral properties of conjugate bases of
1, 3, 5, and 11, as well as conjugate acids of 7 and 8 are provided in the
SI.
Figure 3. Structures and summary of calculated physicochemical properties of 2, 12, and 13. Color-mapped surfaces show the molecular electrostatic
potential (blue is positive, green is neutral, and red is negative).
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orbital, UV−vis spectra, and electrostatic map calculations were
performed using density functional theory modeling on gas-
phase B3LYP/6-31G optimized geometries using Gaussian
09.23
Synthesis of Fluorescent Probes. Seminaphthofluores-
cein, seminaphthorhodafluors, and seminaphthorhodamines
(Figure 1) were synthesized in two to three steps. The initial
step involved the condensation of hydroxybenzophenones with
the corresponding naphthols in a mixture of CH3SO3H/TFA
1:1 at 80 °C for 16−24 h to produce the lactones or
carboxylates. Subsequent Fisher esterification to produce the
methyl ester derivatives was carried out in MeOH catalyzed by
either H2SO4 or HCl. Further alkylation was attained by
treatment of either the carboxylate or methyl ester intermediate
with methyl iodide in the presence of K2CO3 in dimethylfor-
mamide to produce the corresponding methyl ethers. The
required starting materials, 2-(2,4-dihydroxybenzoyl)benzoic
acid, 2-(4-amino-2-hydroxybenzoyl)benzoic acid, 2-(8-hydroxy-
1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline-9-carbonyl)-
benzoic acid, and 1,8-naphthalene derivatives, were synthesized
according to described or modified literature protocols. In
general, overall good yields were obtained for most of the
fluorophores included in this series with the exception of the
condensation products between 2-(2,4- dihydroxybenzoyl)-
benzoic acid and 8-amino naphthol derivatives 7 and 8, where
the major isolated product corresponded to fluorescein. All
compounds were isolated by flash column chromatography or
preparative thin-layer chromatography and characterized by
NMR and high-resolution electrospray ionization mass
spectrometry.
UV−Vis Absorption and Fluorescence Spectroscopy.
UV−vis spectra were collected using a Cary 50 UV−vis
spectrophotometer at room temperature (rt) using a reduced-
volume 1 cm quartz cuvette. Fluorescence spectra were
Figure 4. | Subcellular colocalization of compound 12 in Capan-1 cells. Images of subcellular organelles stained with commercial fluorescent trackers
(top row) are labeled 4’-6-diamidino-2-phenylindole (DAPI) (blue), ER (green), or Mito (green); bottom row contains merged view of compound
12 with fluorescent organelle trackers.
ACS Omega Article
DOI: 10.1021/acsomega.6b00403
ACS Omega 2017, 2, 154−163
158
collected on a Cary Eclipse fluorescence spectrophotometer
(Agilent Technologies). All absorption spectra were reference
corrected. Fluorescence spectra were corrected for the
wavelength-dependent response of the R928 photomultiplier
tube using a manufacturer-generated correction file. Quantum
yields were reported as the average of multiple measurements
using multiple references. EEMs were collected over various
spectral regions, using 5 or 10 nm step sizes for emission and
excitation. The band pass for excitation and emission was 5−10
nm.
Cell Culture. The human PDAC cell line Capan-1 was
obtained from Dr. Rosalie Sears’s laboratory at Oregon Health
and Science University (OHSU) and was maintained in RPMI
medium (Gibco) in a humid atmosphere at 37 °C with 5%
CO2. All media were supplemented with 10% (v/v) fetal bovine
serum (FBS) and 1% (v/v) penicillin/streptomycin. Cell
viability was determined by Cell Titer-Blue assay. Monolayers
of 104 Capan-1 cells were seeded in triplicate in 96-well plates
and incubated with decreasing concentration from 100 μM of
each compound in growth media containing 10% FBS. After 24
h incubation time, 20 μL of Cell Titer-Blue reagent was added
into each well and culture cells were incubated for additional 2
h. Fluorescence intensity in each well was recorded at 560/590
nm using a SpectraMax M5 Microplate Reader. The half-
maximal inhibitory concentrations (IC50) of 2, 12, and 13 were
determined by interpolating values in the graph (% cell viability
vs fluorophore concentration). For the comparison of cellular
uptake rates in Capan-1 cells, the absorbance of the media was
measured as background, and the absorbance of the super-
natant was obtained to determine the cellular uptake, using the
absorbance of 10 μM fluorophore in cell-free media as the
standard reference.
In Vitro Live Cell Imaging. Monolayers of 104 Capan-1
cells were seeded in triplicate in eight-well plates and incubated
for 24 h in growth mediun containing 10% FBS and were
allowed to attach. For subcellular colocalization experiments,
the medium was extracted and cells were washed with
phosphate-buffered saline (PBS), and phenol red-free growth
medium was added to each well. Organelle trackers were added
to each well, and incubated with the fluorophore of interest
(final concentration 0.5 μM) for 1 h. Cells were washed with
PBS and fixed with 2% paraformaldehyde (PFA). Fluorescence
microscopy was carried out using a Zeiss inverted microscope
with an Axioscan fluorescence camera for imaging. The final
concentrations of organelle trackers used were as follows: DAPI
0.5 μM, Mito-tracker green 0.5 μM, and ER-tracker green 1
μM.
Animals. Approval for the use of all animals in this study
was obtained from the Institutional Animal Care and Use
Committee (IACUC) at OHSU. Male CD-1 mice weighing
22−24 g were purchased from Charles River Laboratories
(Wilmington, MA). Genetically engineered mouse models of
PDAC based on the targeted expression of an oncogenic KRAS
mutation (KRASG12D) in the mouse pancreas were used to
model the human disease. Mice expressing the KRAS mutation
alone, termed “KC mice”, develop the full range of intraductal
neoplastic lesions (PanINs) that are histologically indistinguish-
able from human PanINs. The mice develop PanINs with 100%
penetrance, but these lesions do not progress to metastatic
disease.19,24 A modification of the KC mouse that was
developed in the laboratory of Dr. Rosalie Sears (Department
of Molecular & Medical Genetics, Oregon Health and Science
University) was used to more closely model human PDAC.
This mouse model, termed “KMC mice”, included over-
expression of the wild-type Myc oncogene,25,26 similar to their
Figure 5. In vivo organ biodistribution kinetics of synthesized compounds vs MB-normalized fluorescence intensity. Mean organ fluorescence
intensity following systemic administration of (A) compound 2, (B) compound 12, (C) compound 13, or (D) MB.
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previously published breast cancer mouse models.27 This PC
mouse model developed PanIN lesions by 10 weeks of age and
rapidly progressed to PDAC, including metastatic disease, more
closely representing the human disease (Sears Lab OHSU,
unpublished data). Both KC and KMC mice were used to
assess compound 12 accumulation in PDAC. All animals were
placed on 5V75 chlorophyll-free diet from TestDiet (St. Louis,
MO) 1 week before any imaging studies. Before surgery, mice
were anaesthetized with 100 mg/kg ketamine and 10 mg/kg
xylazine (Patterson Veterinary, Devens, MA). The peritoneal
cavity was surgically exposed by removal of the overlying skin
and muscle tissue to image fluorophore biodistribution
following intravenous injection.
Intraoperative Fluorescence Imaging System. In vivo
murine biodistribution images and macroscopic images of
resected tissues were acquired using a custom-built small animal
imaging system capable of real-time color and fluorescence
imaging. The imaging system consists of a QImaging EXi Blue
monochrome camera (Surrey, British Columbia, CA) for
fluorescence detection with a removable Bayer filter for
collecting co-registered color and fluorescence images. A
PhotoFluor II light source (89 North, Burlington, VT) was
focused onto the surgical field through a liquid light guide and
used unfiltered for white light illumination. For fluorescence
detection, the light source was filtered using a 545 ± 12.5, 620
± 30, or 650 ± 22.5 nm bandpass excitation filter for
compounds 2 and 12, compound 13, and MB fluorescence
excitation, respectively. The resultant fluorescence was
collected using a 605 ± 35, 700 ± 37.5, or 720 ± 30 nm
bandpass emission filter for compounds 2 and 12, compound
13, and MB image collection, respectively. All filters were
obtained from Chroma technology (Bellows Falls, VT).
Camera exposure times ranged from 50 to 200 ms for
fluorescence image collection. All images collected for
comparison between treatment groups were acquired with the
same exposure time and are displayed under equal normalized
brightness and contrast levels where indicated.
Systemic Administration of Fluorescent Compounds.
For initial in vivo testing and biodistribution studies, 100 nmol
of compounds 2, 12, and 13 were injected systemically.
Fluorophores were diluted in PBS. For comparison with
previous studies, 120 nmol MB was injected systemically. Mice
were administered blank PBS for control images (n = 3 mice
Figure 6. Ex vivo microscopy images of control and PDAC tissue slides stained with compound 12 and real-time intraoperative fluorescence imaging
of PDAC tumor-bearing mice injected with compound 12. (A) Microscopy images of compound 12 stained pancreas tissue. (B) The location of the
pancreas in the peritoneal cavity is shown outlined in yellow, with (top) and without (bottom) compound 12 administration. (C) Macroscopic
images of resected pancreas tissue from PDAC tumor-bearing mice ex vivo either following systemic administration of compound 12 (top) or from
an uninjected PDAC tumor-bearing mouse (bottom) confirming the lack of pancreas fluorescence without 12.
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Figure 7. Ex vivo pathology of resected PDAC tissue. Microscopy images of H&E, pan-cytokeratin, and compound 12 stained slides showing
representative (A) small, (B) medium, and (C) large-duct-type adenocarcinoma tissue as well as (D) acinar cells resected from PDAC-bearing mice
injected with 12. Pan-cytokeratin antibody staining highlights PDAC cells. Comparison of the fluorescence images obtained with 12 to those
obtained with the antibody confirms their similar PDAC-staining patterns.
ACS Omega Article
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per group, 5 groups). For PDAC tumor mice model testing 100
nmol of compound 12 was injected systemically (n = 5 mice).
In Vivo Biodistribution Imaging. The biodistribution of
compounds 2, 12, and 13 was assessed using the intraoperative
fluorescence imaging system to collect images of the peritoneal
cavity. The peritoneal cavity was exposed, and images were
collected so that the bladder, adipose tissue, intestine, kidney,
liver, muscle, pancreas, spleen, and stomach were visible within
the field of view. For initial biodistribution studies, images were
collected immediately after injection and at 5, 15, 30, 60, 120,
and 240 min following injection. For MB injected mice, images
were collected for the same time course, but only up to 60 min
due to the rapid clearance of MB. For PDAC tumor-bearing
mice, images were collected immediately after injection and at
5, 15, 30, 60, and 90 min following injection. Vehicle-injected
control animals were imaged for the same time course as the
fluorophore-injected animals for initial testing or immediately
following injection only for studies involving MB or PDAC
tumor-bearing mice to assess tissue autofluorescence for
comparison to injected animals. Fluorophore biodistribution
kinetics were measured using region-of-interest analysis on
images collected of the peritoneal cavity. Mean fluorescence
intensities in each organ or tissue type were measured from
images collected at each time point. All intensities were
normalized to the muscle intensity at that time point by
dividing by the measured muscle intensity. Using the
normalized fluorescence intensities for each organ or tissue
type, mean intensities were calculated for each group. Upon
completion of initial biodistribution studies, animals were
euthanized and their organs were resected. Macroscopic images
of the resected organs were collected using the intraoperative
fluorescence imaging system, and the mean fluorescence
intensity of each resected organ was measured using region-
of-interest analysis. Fluorescence intensities were normalized to
the muscle intensity in the same manner as in vivo
measurements. Mean intensities were calculated for each
group using the normalized values. For biodistribution studies
in PDAC tumor-bearing mice, only the pancreas was resected
and imaged following euthanasia.
Ex Vivo Fluorescence Microscopy, Pathology, and
Immunofluorescence Staining. The resected pancreas
tissue from compound 12 in vivo biodistribution studies with
PDAC tumor-bearing mice was fixed with 2% PFA for 12 h,
flash frozen in optimal cutting temperature (OCT) compound
with liquid nitrogen, and stored at −80 °C. Cryosections were
cut at 10 m onto Superfrost Plus slides (Fisherbrand, Fisher
Scientific). Slides were mounted with Fluoromount-G (South-
ern Biotech, Birmingham, AL) and coverslipped. Serial sections
were obtained for cytokeratin immunofluorescence microscopy,
enabling imaging of compound 12 and immunofluorescence
labeling with 0.01 mg/mL of directly labeled anti-pan-
cytokeratin conjugated to AlexaFluor 488 (eBioscience, San
Diego, CA). Briefly, slides were rinsed with PBS for 2 min to
remove residual OCT. Then, slides were fixed by immersion in
2% PFA for 15 min and washed with PBS for 5 min three times.
Primary antibody was incubated on the slides for 1 h at rt.
Following incubation, slides were washed with PBS three times
for 5 min each, then postfixed with PFA for 15 min, and washed
with PBS once for 5 min before mounting with Fluoromount-
G. For cytokeratin immunofluorescence controls, serial sections
were stained using the above immunofluorescence procedure
but without antibody present in the staining solution that was
incubated on the slides. For H&E pathological analysis, slides
previously stained for cytokeratin expression were unmounted
and rinsed with PBS to remove residual mournting media
before H&E staining. Images were acquired on an Axio
Observer inverted fluorescence microscope (Zeiss, Thornwood,
NY) at 10, 20, or 40× magnification. A PhotoFluor II was used
unfiltered for H&E color images and filtered using a 545 ± 12.5
or 470 ± 20 nm bandpass excitation filter for compound 12 or
Atto 488 excitation, respectively. Color images were collected
using an Axiocam 105 camera (Zeiss) and fluorescence images
were collected using an Axiocam 506 camera (Zeiss), where a
605 ± 35 or 525 ± 25 nm bandpass emission filter was used for
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